What we do

Glycobond was established in 2011 by researchers at Linköping University (Sweden). The privately held and independent company is located in Linköping.

Glycobond uses recombinant technology to produce carbohydrate-binding peptides with defined specificities for use primarily in diagnosis and monitoring of liver diseases and cancer.

The company’s first product is a CE-marked assay for aid in diagnosis of primary liver cancer, HepaCheC®.

Product

HepaCheC® ELISA kit

An in vitro diagnostic device for aid in diagnosis of primary liver cancer (hepatocellular carcinoma).

Technology

Glycobond uses recombinant technology to produce carbohydrate-binding peptides with defined specificities for use primarily in diagnosis and monitoring of liver diseases and cancer.